VC/I  Xontogeny

     Office Locations:

240 Newbury Street, Suite 201
Boston, MA 02116



  • Seed



  • Life Sciences & Healthcare



    Based in Boston, MA, Xontogeny seeks to accelerate the development of life science technologies by providing entrepreneurs with funding options as well as the leadership, strategic guidance and operational support necessary to increase the probability of success in early drug and technology development. Through a differentiated approach, the Xontogeny team partners with founding scientists and entrepreneurs to support their vision while allowing a more efficient development model that benefits company founders and early equity holders. Xontogeny has made a number of seed investments and continues to incubate a pipeline of early-stage life sciences companies across a wide variety of modalities and therapeutic areas. Along with Perceptive Advisors, the firm developed the Perceptive Xontogeny Venture Fund, LP, solely focused on investment in early-stage life science companies. The PXV Fund was oversubscribed and has closed with $210 million in commitments.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Ben Askew Partner
    Chris Garabedian Chairman & CEO
    Fred Callori SVP, Corporate Development
    Shobha Parthasarathi VP


    Portfolio companies include:


    Recent News: